UPDATED May 05, 2024
Companys with strong funding and high growth potential
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
CASI | US$2.75 | 17.5% | 10.0% | US$36.3m | US$12.00 | PS1.1x | E57.6% | n/a | Pharmaceuticals & Biotech | ||
ARGN.F | €373.50 | -2.7% | n/a | €21.6b | €457.57 | PS18.1x | E56.1% | n/a | Pharmaceuticals & Biotech | ||
0QFD | US$115.76 | 11.4% | -5.6% | US$47.9b | US$131.09 | PS9.1x | E68.7% | n/a | Pharmaceuticals & Biotech | ||
FRLN | US$6.48 | -0.2% | -21.7% | US$28.3m | US$8.25 | PS45.4x | E60.7% | n/a | Pharmaceuticals & Biotech | ||
MIRM | US$25.84 | 3.1% | -2.0% | US$1.2b | US$48.91 | PS6.5x | E65.6% | n/a | Pharmaceuticals & Biotech | ||
OXBL | UK£3.30 | 28.0% | -20.2% | UK£328.0m | UK£4.29 | PS3.7x | E101.6% | n/a | Pharmaceuticals & Biotech | ||
IVBX.F | HK$5.21 | 4.2% | 0.4% | HK$65.7b | HK$7.11 | PS9.8x | E51.0% | n/a | Pharmaceuticals & Biotech | ||
ARGXB | €362.90 | 5.4% | -0.5% | €21.6b | €438.71 | PS18.3x | E56.1% | n/a | Pharmaceuticals & Biotech | ||
0QW0 | €363.50 | 3.9% | 0.9% | €21.6b | €439.44 | PS18.3x | E56.1% | n/a | Pharmaceuticals & Biotech | ||
SRRA | US$54.99 | 0.06% | 179.4% | US$1.3b | US$55.00 | PB5.1x | E69.5% | n/a | Pharmaceuticals & Biotech | ||
BINVS | kr34.75 | 0% | n/a | kr2.1b | kr124.66 | PS6.7x | E64.4% | n/a | Pharmaceuticals & Biotech | ||
XSPRAS | kr50.85 | 0% | n/a | kr1.1b | kr153.70 | PB1.7x | E221.0% | n/a | Pharmaceuticals & Biotech | ||
FYBD | €63.30 | 0% | -11.1% | €911.0m | €118.80 | PS13.3x | E80.8% | n/a | Pharmaceuticals & Biotech | ||
ZLAB | US$16.25 | 0.8% | -56.1% | US$1.6b | US$52.51 | PS6x | E62.0% | n/a | Pharmaceuticals & Biotech | ||
KALV | US$12.13 | 10.2% | 27.1% | US$511.7m | US$29.80 | PB5.8x | E59.8% | n/a | Pharmaceuticals & Biotech | ||
PTGX | US$26.09 | 2.1% | 4.7% | US$1.5b | US$43.00 | PS25.5x | E50.0% | n/a | Pharmaceuticals & Biotech | ||
ARCT | US$27.27 | 2.4% | -4.4% | US$734.3m | US$67.89 | PS4.4x | E60.0% | n/a | Pharmaceuticals & Biotech | ||
MSB | AU$1.16 | 6.5% | 17.3% | AU$1.3b | AU$1.10 | PS117x | E56.8% | n/a | Pharmaceuticals & Biotech | ||
LLAI | UK£0.26 | -13.3% | -52.7% | UK£8.0m | UK£2.20 | PS217.9x | E88.7% | n/a | Pharmaceuticals & Biotech | ||
GERN | US$3.72 | -10.1% | 35.3% | US$2.3b | US$6.07 | PS4243.2x | E64.9% | n/a | Pharmaceuticals & Biotech | ||
ATNM | US$8.84 | 19.8% | 2.2% | US$266.9m | US$25.47 | PS3250.4x | E68.3% | n/a | Pharmaceuticals & Biotech | ||
LEGN | US$45.26 | 0.3% | -34.2% | US$8.3b | US$86.34 | PS28.9x | E61.3% | n/a | Pharmaceuticals & Biotech | ||
MRNA | US$122.13 | 9.4% | -7.3% | US$47.9b | US$138.31 | PS9.1x | E68.7% | n/a | Pharmaceuticals & Biotech | ||
0JXI | US$233.79 | 17.1% | -25.0% | US$4.9b | US$374.21 | PB12.4x | E61.4% | n/a | Pharmaceuticals & Biotech |